-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although the use of disease modifying therapy (DMT) has changed the long-term prognosis of patients with remission-relapsing multiple sclerosis (RRMS), its prospects in the treatment of secondary progressive multiple sclerosis (SPMS) But more cautious
.
However, clinicians need to consider treating SPMS patients, especially when there is evidence of significant inflammatory activity
For the first time in more than a decade, a new treatment that has the potential to reduce long-term disability has been authorized for the treatment of SPMS
.
In the EXPAND test, siponimod (siponimod)
Immunity in achieving these benefits, high efficacy of treatment is superior to the low efficacy of the treatment is uncertain
Patients with active SPMS who received high-efficiency treatment had a lower recurrence frequency than those who received low-efficiency treatment (hazard ratio [HR] 0.
7, P=0.
006)
The significance of this study lies in the discovery that among SPMS patients undergoing treatment, high-efficiency therapy is superior to low-efficiency therapy in reducing the recurrence of active SPMS patients, but not for inactive SPMS patients
.
However, more effective treatments have no advantage in reducing the progression of disability in this patient population
In SPMS patients receiving treatment, high-efficiency therapy is better than low-efficiency therapy in reducing the recurrence of active SPMS patients, but for inactive SPMS patients, it is not.
In SPMS patients receiving treatment, high-efficiency therapy is reducing activity The recurrence of SPMS patients is better than ineffective therapies, but not for inactive SPMS patients
Original source:
Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, Madueño SE, Patti F, Edan G, Debouverie M, Pelletier J, Ozakbas S, Amato MP, Clavelou P, Grammond P, Boz C , Buzzard K, Skibina O, Ciron J, Gerlach O, Grand'Maison F, Lechner-Scott J, Malpas MPsych CliNeuro C, Butzkueven H, Vukusic S, Kalincik T; MSBase and OFSEP Study Groups.
Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
Neurology.
2021 Jun 30:10.
1212/WNL.
0000000000012354.
doi: 10.
1212/WNL.
Leave a message here
